From the people we work with

"Akaal Pharma is a clinical-stage biotech company focused on the discovery and development of novel small molecule drugs for the treatment of inflammation and autoimmune disease.

Akaal Pharma has worked with Watermark and Grant Jacobsen since 2008 principally to obtain patent protection for their small molecule drugs. Throughout the relationship, Watermark has taken a commercially orientated approach with a strong focus on value. Particularly, Watermark has been conscious of Akaal’s status as a small start-up and has consistently offered cost relevant advice, enabling Akaal to defer numerous actions and associated costs.

Watermark has ensured that the scope of Akaal’s patent filings was aligned with the commercial strategy of the company. Of particular note was the issuance of a United States patent which broadly covered Akaal’s key molecules.

Furthermore, Watermark has taken a pragmatic approach to Akaal’s ongoing developments and has often recommended that a patent application not be filed, if the value of such a filing was seen as low. This, again, positively impacted Akaal’s cost position.

Akaal Pharma highly recommends Watermark’s expertise in patents and their commercial focus on intellectual property."

Dr Gurmit Gill
Akaal Pharma Pty Ltd

"Clover Corporation is a technology driven company striving to deliver a range of innovative food supplements through both patented science, and strong brands.

Watermark took over management of Clover Corporation's trade mark portfolio of over 90 trade mark properties in 2011.  Prior to this time, Clover Corporation's trade mark properties were managed by several different service providers.  Watermark's approach has been distinguished by it's strong focus on ensuring that the trade marks Clover Corporation files and maintains are aligned with the commercial strategy of the company. They have not been afraid to suggest that we limit jurisdictions, or lapse non-working assets.

More recently, I have worked with Watermark in the patent space. Clover Corporation has been striving to focus the commercialisation of it's technology in areas of real commercial value. While I had been aware of the capacity to map and analyse patent landscapes for commercial information as a means of driving innovation, I was pleasantly surprised that the cost of Watermark carrying out this work for Clover Corporation was less than a quarter of the estimate that I had been given elsewhere.  

Furthermore, Watermark's flexibility and engagement with my technical staff in carrying out the task delivered an end product which was highly informative, and persuasive in Board meetings that I ran in which we addressed corporate innovation and commercialisation strategy.

I can highly recommend Watermark's trade mark management and technology and market analysis services."

Dr Craig Patch, Chief Innovation Officer
Clover Corporation

"Watermark has a long association with Barker Brettell and has assisted our UK clients in protecting their intellectual assets in Australia and New Zealand. As well as filing and registering patents, trade marks and designs, Watermark has provided strategic advice to our clients about enforcing their intellectual property rights. We at Barker Brettell are looking forward to continuing our strong relationship with Watermark into the future".

John Lawrence
Barker Brettell

Watermark has made a significant contribution to the value of our company. Thanks to the razor-sharp intellect of our Watermark advisors, their deep understanding of the patent process in a number of jurisdictions, and their flexibility in working with our inventors, our patent applications have progressed rapidly. This, together with the portfolio management strategies that Watermark has helped us to put in place, and their advice on our intellectual assets more generally, have resulted in a solid and extensive IP portfolio for our company, which has been key in securing investment and other funding."

Dr Jonathan Lacey, CEO
Ofidium Pty Ltd